290 related articles for article (PubMed ID: 23241893)
1. Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.
Schmiedel BJ; Nuebling T; Steinbacher J; Malinovska A; Wende CM; Azuma M; Schneider P; Grosse-Hovest L; Salih HR
J Immunol; 2013 Jan; 190(2):821-31. PubMed ID: 23241893
[TBL] [Abstract][Full Text] [Related]
2. RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.
Schmiedel BJ; Scheible CA; Nuebling T; Kopp HG; Wirths S; Azuma M; Schneider P; Jung G; Grosse-Hovest L; Salih HR
Cancer Res; 2013 Jan; 73(2):683-94. PubMed ID: 23139212
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans.
Baessler T; Krusch M; Schmiedel BJ; Kloss M; Baltz KM; Wacker A; Schmetzer HM; Salih HR
Cancer Res; 2009 Feb; 69(3):1037-45. PubMed ID: 19155305
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL).
Buechele C; Baessler T; Wirths S; Schmohl JU; Schmiedel BJ; Salih HR
Leukemia; 2012 May; 26(5):991-1000. PubMed ID: 22064350
[TBL] [Abstract][Full Text] [Related]
5. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
8. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
9. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway.
Panizo S; Cardus A; Encinas M; Parisi E; Valcheva P; López-Ongil S; Coll B; Fernandez E; Valdivielso JM
Circ Res; 2009 May; 104(9):1041-8. PubMed ID: 19325147
[TBL] [Abstract][Full Text] [Related]
10. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.
Baessler T; Charton JE; Schmiedel BJ; Grünebach F; Krusch M; Wacker A; Rammensee HG; Salih HR
Blood; 2010 Apr; 115(15):3058-69. PubMed ID: 20008791
[TBL] [Abstract][Full Text] [Related]
11. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
12. 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.
Buechele C; Baessler T; Schmiedel BJ; Schumacher CE; Grosse-Hovest L; Rittig K; Salih HR
Eur J Immunol; 2012 Mar; 42(3):737-48. PubMed ID: 22144129
[TBL] [Abstract][Full Text] [Related]
13. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
14. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions.
Wang Y; Chen C; Dong F; Ma S; Xu J; Gong Y; Cheng H; Zhou Y; Cheng T; Hao S
Sci China Life Sci; 2015 Dec; 58(12):1288-98. PubMed ID: 26588911
[TBL] [Abstract][Full Text] [Related]
15. Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.
Pittari G; Fregni G; Roguet L; Garcia A; Vataire AL; Wittnebel S; Amsellem S; Chouaib S; Bourhis JH; Caignard A
Bone Marrow Transplant; 2010 May; 45(5):862-71. PubMed ID: 19802033
[TBL] [Abstract][Full Text] [Related]
16. Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.
Arai A; Mizoguchi T; Harada S; Kobayashi Y; Nakamichi Y; Yasuda H; Penninger JM; Yamada K; Udagawa N; Takahashi N
J Cell Sci; 2012 Jun; 125(Pt 12):2910-7. PubMed ID: 22454522
[TBL] [Abstract][Full Text] [Related]
17. Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration.
Hsu CJ; Lin TY; Kuo CC; Tsai CH; Lin MZ; Hsu HC; Fong YC; Tang CH
J Cell Biochem; 2010 Sep; 111(1):138-47. PubMed ID: 20506523
[TBL] [Abstract][Full Text] [Related]
18. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells.
Lion E; Smits EL; Berneman ZN; Van Tendeloo VF
Leuk Res; 2009 Apr; 33(4):539-46. PubMed ID: 18845337
[TBL] [Abstract][Full Text] [Related]
20. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
Munker R; Andreeff M
Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
